Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is a U.S.-based pharmaceutical company centered on Endari®, an oral L-glutamine therapy used in sickle cell disease. The company commercializes the product through distributors and pharmacy channels in the U.S. and also sells into the MENA region, while relying on external financing to support operations.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaCommercial sales of Endari®, the company's core prescription therapy for sickle cell disease.
Sales routed through nonexclusive distributors, PBMs, and pharmacy networks in the United States.
Product sales in the Middle East and North Africa, which add geographic diversification but remain smaller than U.S. sales.
Tuotteet
Raportoitu · osuus liikevaihdosta- Endari US72,7 %
- Endari International25,5 %
- Other1,8 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Emmaus sells primarily to patients with sickle cell disease through a healthcare reimbursement chain that includes distributors, pharmacies, PBMs, Medicaid, Medicare, and commercial payors. The company also serves buyers and channel partners in the MENA region, where sales timing can be uneven. Demand depends heavily on reimbursement access and physician prescribing of Endari® versus generic L-glutamine alternatives.
Patients prescribed Endari® for sickle cell disease; they buy through pharmacies, with reimbursement support critical to access.
Nonexclusive distributors, specialty pharmacies, and PBMs that move Endari® into retail and specialty pharmacy networks.
Medicare and Medicaid programs that reimburse Endari® and materially affect affordability and volume.
Private insurers and managed care organizations that determine formulary access and reimbursement rates.
Regional buyers and channel partners purchasing Endari® in the Middle East and North Africa.
Strategia
Emmaus is focused on stabilizing and rebuilding Endari® sales after generic L-glutamine entry pressured U.S. demand and reimbursement rates. Near term, the company is reducing costs, relying on distributors, and seeking additional capital or strategic transactions to fund operations and preserve commercialization capacity.
Generic L-glutamine competition has reduced U.S. sales and pressured pricing.
Cash balances are very low and the company needs external funding to continue operations.
Lower fixed costs help offset revenue pressure and extend runway.
Maantiede
The business is anchored in the United States, where Endari® is sold through national distribution and reimbursement channels. Emmaus also reports sales in the MENA region, which can fluctuate by timing and helped partially offset U.S. weakness in recent quarters. The company does not disclose manufacturing locations in the provided excerpts, but its supply chain includes API purchases under arrangements with Telcon.
Riskit
The company faces acute liquidity risk because cash is minimal and operating losses continue, making external financing essential. Commercial risk is also high: generic competition has already reduced Endari® sales and reimbursement rates, while MENA sales can be volatile by timing. Additional pressure comes from debt service, API supply obligations, and valuation-sensitive financing instruments.
Cash and cash equivalents are very low and the company says it lacks sufficient operating capital without new funding.
Kohdistuu: Ability to fund operations and debt obligations
ANI's generic launch has adversely affected Endari® sales and reimbursement rates.
Kohdistuu: U.S. Endari® revenue and pricing
Endari® depends on Medicare, Medicaid, and commercial coverage for volume and affordability.
Kohdistuu: Prescription demand and net revenue realization
Convertible notes, other notes payable, and related-party financing can increase interest expense and dilution risk.
Kohdistuu: Capital structure and earnings
Management noted that regional sales timing can move quarterly results materially.
Kohdistuu: Quarterly revenue volatility
Kirjanpito
Harkinnanvaraiset erätDistributor and reimbursement arrangements can affect when and how much revenue is recognized.
Vaikutus: Net revenue timing and gross-to-net deductions
Changes in valuation can create large non-cash gains or losses in other income/expense.
Vaikutus: Earnings volatility
Debt instruments affect interest expense, extinguishment gains/losses, and liquidity disclosures.
Vaikutus: Net loss and capital structure
Equity award valuation assumptions affect compensation expense and dilution analysis.
Vaikutus: Operating expense and diluted share count
Office lease modifications and lease obligations affect G&A expense and liabilities.
Vaikutus: Reported operating costs and balance sheet obligations
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Amicus Therapeutics, Inc.
Pharmaceutical Preparations
ENDRA Life Sciences Inc.
NDRA · Electromedical & Electrotherapeutic Apparatus
Entera Bio Ltd.
ENTX · Biological Products, (No Diagnostic Substances)
Journey Medical Corp
DERM · Pharmaceutical Preparations
Journey Medical Corp is a U.S.-focused pharmaceutical company that commercializes branded dermatology products and recently added Emrosi, an FDA-approved…
Tempus AI, Inc.
TEM · Services-Computer Programming, Data Processing, Etc.
Päivitetty: 28.4.2026